NanoInk President and CEO, Cedric Loiret-Bernal, M.D., to Speak at BIO 2006 Annual International Convention

Apr 06, 2006, 01:00 ET from NanoInk, Inc.

    CHICAGO, April 6 /PRNewswire/ -- NanoInk, Inc., today announced that the
 Company's President and Chief Executive Officer, Dr. Cedric Loiret-Bernal will
 be a featured guest speaker at the BIO 2006 Annual International Convention
 being held in Chicago.
      Logo: )
     Dr. Loiret-Bernal, a leading expert on nanoencryption, will speak about
 the Company's Nanoencryption(TM) technology and its use by pharmaceutical
 customers and DPN(R) technology for bio-nanoarrays.  The presentation will
 begin at 9:30 a.m. CDT on Wednesday, April 12, 2006, in Room C, McCormick
 Place South, Level 3, Exhibit Hall A of the McCormick Place Convention Center.
 The McCormick Place Convention Center is located at 2301 South Lake Shore
 Drive, Chicago, IL.
     Dr. Loiret-Bernal is the former Chief Executive Officer and co-founder of
 GeneProt, Inc., and has also held many other senior positions in the
 pharmaceutical and biomedical industries at Abbott Laboratories, Haemonetics,
 and Porges-Synthelabo.  Dr. Loiret-Bernal holds a doctor of medicine degree,
 summa cum laude, from the University of Bordeaux and has an MBA degree from
 the J.L. Kellogg School of Management, Northwestern University.
     "BIO 2006 is a wonderful opportunity to share the potential value of our
 proprietary Nanoencryption(TM) technology that helps prevent counterfeit and
 illegal pharmaceuticals from entering the global markets," said Dr.
 Loiret-Bernal.  "I will also discuss the potential of our DPN(R) technology
 that enables the deposition of a variety of biomolecules for the development
 of bio-nanoarrays."
     Nanoencryption(TM) technology is the one-stop, deeply covert encryption
 and authentication solution to prevent counterfeit pharmaceuticals from
 entering the market.  Counterfeit pharmaceuticals can be easily identified by
 the absence of special coded nanoencryption.  During the authentication
 process, illegal products are flagged as mismatches and removed from the
 supply chain.  Using NanoInk's proprietary technology, pharmaceutical
 manufacturers and enforcement agencies can identify and significantly reduce
 counterfeiting and illegal diversion.
     NanoInk's Scientific Founder, Chad A. Mirkin, Ph.D., Director of the
 International Institute of Nanotechnology, George B. Rathmann Professor of
 Chemistry, Professor of Medicine, Professor of Material Sciences &
 Engineering, Northwestern University, will discuss his most recent DPN(R)
 research work at The Illinois Pavilion, McCormick Place Convention Center, at
 3 pm CDT, on Tuesday, April 11, 2006.  During this presentation, his work will
 be recognized with an award presented by the Illinois Biotech Organization
     About NanoInk
     NanoInk, Inc. is an emerging growth technology company specializing in
 nanometer-scale manufacturing and applications development for the lifescience
 and semiconductor industries.  With DPN(R), a patented and proprietary
 nanofabrication technology that allows for unmatched flexibility, accuracy and
 also its high-resolution Nanoencryption(TM) technology, NanoInk is able to
 offer its pharmaceutical customers innovative solutions to fight
 counterfeiting and illegal diversion of blockbuster pharmaceutical products.
 Other key applications include nanoscale additive repair, and nanoscale rapid
 prototyping.  Located in the new Illinois Science + Technology Park, north of
 Chicago, NanoInk currently has over 100 patents and patent applications filed
 worldwide and has licensing agreements with Northwestern University, Stanford
 University, and the University of Illinois at Urbana-Champaign.  For more
 information on products and services offered by NanoInk, Inc., see .

SOURCE NanoInk, Inc.